Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefits

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4272-4281

  Steiner, Hans Herbert ^a   Bonsanto, Matteo Mario ^a   Beckhove, Philipp ^a   Brysch, Michael ^a   Geletneky, Karsten ^a   Ahmadi, Rezvan ^a   Schuele Freyer, Rebecca ^a   Kremer, Paul ^a   Ranaie, Golamreza ^a   Matejic, Dejana ^a   Bauer, Harald ^a   Kiessling, Marika ^a   Kunze, Stefan ^a   Schirrmacher, Volker ^a   Herold Mende, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR VACCINE; CANCER VACCINE;

ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GAMMA RADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MEMORY CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL CULTURE; VACCINATION; ACTIVE IMMUNIZATION; AVULAVIRUS; CASE CONTROL STUDY; CELL CULTURE; CENTRAL NERVOUS SYSTEM TUMOR; FEASIBILITY STUDY; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

AVULAVIRUS; CANCER VACCINES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 16544392098     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.038     Document Type: Article

References (28)

1. Davies FG, Freels S, Grutsch J, et al: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance. Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88:1-10, 1998
2. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
3. Kleihues P, Louis DN, Scheithauer BW, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2002
4. Herold-Mende C, Mueller MM, Bonsanto MM, et al: Clinical impact and functional aspects of tenascin expression during glioma progression. Int J Cancer 98:362-369, 2002
5. Castelli MG, Chiabrando C, Fanelli R, et al: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49:1505-1508, 1989
6. Maxwell M, Galanopoulos T, Neville-Golden J, et al: Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76:799-804, 1992
7. Huettner C, Paulu W, Roggendorf W: Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317-322, 1995
8. Pollack IF, Okada H, Chambers WH: Exploitation of immune mechanisms in the treatment of central nervous system cancers. Semin Pediatr Neurol 7:131-143, 2000
9. Fakhrai H, Dorigo O, Shawler DL, et al: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93:2909-2914, 1996
10. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736, 1996
11. Kurpad SN, Wikstrand CJ, Bigner DD: Immunobiology of malignant astrocytomas. Semin Oncol 21:149-161, 1994
12. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93:10399-10404, 1996
13. Ni HT, Spellman SR, Jean WC, et al: Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1-9, 2001
14. Naujocks G, Serwe M, Bayer TA, et al: Adoptive transfer via immune T-lymphocytes of effective anti-tumor immunity against a malignant rat glioma in the brain. Int J Oncol 11:249-254, 1997
15. Matzinger P: The danger model: A renewed sense of self. Science 296:301-305, 2002
16. Nelson NJ: Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 91:1708-1710, 1999
17. Schirrmacher V, Haas C, Bonifer R, et al: Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6:63-73, 1999
18. Washburn B, Schirrmacher V: Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 21:85-93, 2002
19. Yu JS, Wheeler CJ, Zeltzer PM, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001
20. Feuerer M, Beckhove P, Bai L, et al: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T-cells from bone marrow. Nat Med 7:452-458, 2001
21. Wikstrand CJ, Reist CJ, Archer GE, et al: The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target. J Neurovirol 4:148-158, 1998
22. Chi DD, Merchant RE, Rand R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152, 1997
23. Ahlert T, Sauerbrei W, Bastert G, et al: Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 15:1354-1366, 1997
24. Schirrmacher V, Ahlert T, Pröbstle T, et al: Immunization with virus-modified tumor cells. Semin Oncol 25:677-696, 1998
25. Termeer CC, Schirrmacher V, Bröcker EB, et al: Newcastle disease virus infection induces a B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7:316-323, 2000
26. von Hoegen P, Zawatzky R, Schirrmacher V: Modification of tumor cells by a low dose of Newcastle disease virus: III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon alpha/beta. Cell Immunol 126: 80-90, 1990
27. Selker RG, Shapiro WR, Burger P, et al: The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external beam radiation therapy, and carmustine. Neurosurgery 51:343-355, 2002
28. Schneider T, Gerhards R, Kirches E, et al: Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 53:39-46, 2001